Janux Therapeutics (NASDAQ:JANX) Shares Down 3.6%

Janux Therapeutics, Inc. (NASDAQ:JANX) shares traded down 3.6% during trading on Tuesday . The stock traded as low as $48.11 and last traded at $48.11. 192,022 shares were traded during mid-day trading, a decline of 73% from the average session volume of 721,013 shares. The stock had previously closed at $49.89.

Analyst Ratings Changes

Several brokerages have recently issued reports on JANX. Cantor Fitzgerald restated an “overweight” rating and issued a $100.00 target price on shares of Janux Therapeutics in a report on Monday. Scotiabank lowered their price objective on shares of Janux Therapeutics from $47.00 to $42.00 and set a “sector perform” rating for the company in a research note on Friday, August 9th. HC Wainwright reissued a “buy” rating and issued a $63.00 target price on shares of Janux Therapeutics in a research note on Monday, August 19th. Wedbush reaffirmed an “outperform” rating and set a $74.00 price target on shares of Janux Therapeutics in a research report on Thursday, August 8th. Finally, Stifel Nicolaus assumed coverage on Janux Therapeutics in a report on Friday, September 6th. They issued a “buy” rating and a $70.00 price objective for the company. One equities research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $66.13.

Janux Therapeutics Trading Down 0.9 %

The company has a market cap of $2.56 billion, a PE ratio of -40.89 and a beta of 3.57. The stock has a 50 day moving average price of $42.99 and a 200 day moving average price of $44.15.

Janux Therapeutics (NASDAQ:JANX) last announced its earnings results on Wednesday, August 7th. The company reported ($0.11) EPS for the quarter, beating analysts’ consensus estimates of ($0.31) by $0.20. Janux Therapeutics had a negative net margin of 291.17% and a negative return on equity of 8.78%. The firm had revenue of $8.90 million for the quarter, compared to analysts’ expectations of $0.77 million. The business’s revenue for the quarter was up 709.1% on a year-over-year basis. Equities analysts expect that Janux Therapeutics, Inc. will post -1.18 EPS for the current fiscal year.

Insider Activity

In related news, major shareholder Ventures Xi L.P. Avalon sold 158,031 shares of the company’s stock in a transaction that occurred on Thursday, September 12th. The stock was sold at an average price of $47.00, for a total value of $7,427,457.00. Following the sale, the insider now owns 2,959,175 shares in the company, valued at approximately $139,081,225. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Over the last ninety days, insiders sold 268,578 shares of company stock worth $12,071,151. Insiders own 35.40% of the company’s stock.

Institutional Trading of Janux Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the company. Swiss National Bank grew its holdings in shares of Janux Therapeutics by 39.5% during the fourth quarter. Swiss National Bank now owns 31,800 shares of the company’s stock valued at $341,000 after buying an additional 9,000 shares during the last quarter. Janney Montgomery Scott LLC bought a new position in Janux Therapeutics in the 4th quarter valued at approximately $553,000. China Universal Asset Management Co. Ltd. boosted its stake in Janux Therapeutics by 82.4% during the 1st quarter. China Universal Asset Management Co. Ltd. now owns 9,743 shares of the company’s stock valued at $367,000 after purchasing an additional 4,400 shares during the last quarter. Capstone Investment Advisors LLC bought a new stake in shares of Janux Therapeutics in the 1st quarter worth $1,969,000. Finally, Lester Murray Antman dba SimplyRich purchased a new position in shares of Janux Therapeutics in the first quarter worth $300,000. 75.39% of the stock is currently owned by institutional investors.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.